

Notice to attend the extraordinary general meeting of Elos Medtech AB (publ)

The shareholders of Elos Medtech AB (publ), reg. no. 556021-9650, headquartered in Gothenburg (“**Elos Medtech**” or the “**Company**”), are hereby invited to the extraordinary general meeting (the “**EGM**”) on Tuesday, 23 April 2024. The EGM will be held at 14:00 at Torsgatan 5B, 411 04 Gothenburg, Sweden. The meeting venue will open at 13:00 for registration. Registration of participants at the meeting ends when the meeting is called to order.

Right to participation

Shareholders who wish to participate in the proceedings of the EGM must:

- be registered as shareholders in the register of shareholders produced by Euroclear Sweden AB as of Monday, 15 April 2024; and
- notify the Company in accordance with the instructions under the heading “Participation at the general meeting” not later than Wednesday, 17 April 2024.

To be entitled to participate in the EGM, a shareholder whose shares are held in the name of a nominee must, in addition to notifying the Company of their participation in the EGM, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on Monday, 15 April 2024. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting rights registration completed by the nominee no later than Wednesday, 17 April 2024 is taken into account when preparing the register of shareholders.

Participation at the general meeting

Shareholders who wish to participate at the EGM must notify the Company of this not later than on Wednesday, 17 April 2024. The notification can be submitted in writing to the following address: Elos Medtech AB (publ), Extraordinary General Meeting 2024, c/o White & Case Advokat AB, Box 5573, 114 85 Stockholm. The notification may also be submitted electronically and must then be sent to alexander.lausev.mardell@whitecase.com. The notification must include the shareholder’s name, address and personal identity number or corporate registration number, telephone number, and the number of any assistants (a maximum of two) accompanying the shareholder. After registered notification, the notifier will receive a confirmation. If no confirmation is received the notification has not been made correctly.

Shareholders who participate via a proxy must issue a written and dated power of attorney for the proxy. The representative of a legal entity must present a copy of the registration certificate or equivalent authorization documents that show the authorized signatory. The shareholder should send the authorization documents (power of attorney and/or registration certificate) to Elos Medtech at the postal address above or electronically to alexander.lausev.mardell@whitecase.com in due time before the EGM. Proxy forms can be downloaded from Elos Medtech’s website: www.elosmedtech.com.

Proposed agenda

1. Opening of the meeting
2. Election of Chairman of the meeting
3. Election of at least one person to verify the minutes
4. Preparation and approval of the voting list
5. Approval of the agenda
6. Determination of whether the EGM has been duly convened
7. Presentation of statement regarding special examination
8. Closing of the meeting

Proposals for decision

Item 2 - Election of Chairman of the meeting

The board of directors proposes that Johan Thiman is elected Chairman of the EGM, or in his absence, the person appointed by the board of directors.

Item 7 – Presentation of statement regarding special examination

At the annual general meeting held on 3 May 2023, minority shareholders representing more than one tenth of the total number of shares in the Company proposed the appointment of a special examiner. The special examination has now been completed, and the statement regarding the special examination will be presented at the EGM.

The full statement by the special examiner is available at the Company and will upon request be sent to shareholders who provide their address. The special examiner has prepared an executive summary of the special examination, which is provided below.

Executive summary

In the following report, our investigation and conclusions from the special examination of Elos Medtech AB (publ) (“**Elos**”) covering the period 11 June 2021 up until and including 30 April 2023, are presented.

Our assignment has been to examine whether Elos board of directors, individual board members and/or CEO have acted in accordance with applicable legislation and other regulations during a period of approximately two years after the private equity company TA XIII, through EM Intressenter AB, in July 2021 acquired the position as the majority shareholder in Elos. The assignment has been focused on three main areas; (i) Elos’ communication and reporting to the market, (ii) the governance of Elos, and (iii) information included in Elos’ financial reports. Within these areas we have particularly examined Elos’ relationship with the majority shareholder and whether Elos’ minority shareholders have been adversely affected by the board of directors’, individual board members’ and/or CEO’s actions.

Initially, we conclude that Elos is a well-functioning company with adequate routines and processes for decision-making and regulatory compliance. Our assessment is that TA XIII/EM Intressenter AB has been acting as an independent company in relation to Elos. Elos has established internal policies to ensure that the independency is complied with.

The result of our examination does not give rise to any criticism towards Elos’ board of directors, individual board members and/or CEO within the three main areas of the special examination. Accordingly, no actions taken by said parties have been in breach of existing legislation and other applicable regulations. Elos board of directors, individual board members and/or CEO have not had a deviant agenda and have acted in the best interest of Elos and consequently in the best interest of all Elos’ shareholders. No minority shareholders have been adversely affected.

EGM documentation

Documents that shall be held available prior to the EGM pursuant to the Swedish Companies Act will be available at the Company at least two (2) weeks before the EGM. The documentation is sent upon request to shareholders who provide their address.

Information at the EGM

The board of directors and the CEO shall, if any shareholder so requests and the board of directors considers that it can be done without material harm to the Company, provide information about circumstances that may affect the assessment of an item on the agenda.

Gothenburg, March 2024
Elos Medtech AB (publ)
The Board of Directors